Phenotypic drug discovery is experiencing a Renaissance in the pharmaceutical industry, based on its successful track record in delivering first-in-class medicines. This approach offers the promise of delivering both novel targets & chemical matter modulating a disease phenotype of interest. Although phenotypic screening may appear at first sight to be similar to target-based screening, there are some significant differences between the two approaches. These need to be properly considered and addressed to ensure the greatest likelihood of success for phenotypic drug discovery programs. This presentation will cover a range of relevant topics with a goal of providing practical information to help prosecute such programs more effectively from assay design all the way to clinical trials.
Who Should Attend:
Academic scientists considering or using phenotypic screens to discover novel biology and molecular probes.
Industry scientists considering or using phenotypic screens to discover novel targets and clinical candidates.
Commercial providers of reagents, instruments and services used in phenotypic screening.
Attendees will participate in an active dialogue with instructors and other participants on course topics. “Phenotypic Screening: Why, When and How” is not a typical “how to” course, since no clear cut “one size fits all” strategy exists for an endeavor as complex as drug discovery.
How You Will Benefit From This Course?
Attendees will leave this course with:
Practical knowledge of key concepts and strategies in phenotypic screening & drug discovery supported by case studies and literature references to bring back to their organizations.
What is the rationale for phenotypic screening?
When does phenotypic drug discovery provide the most value? What may be the best indications for this strategy?
Not all phenotypic assays are created equal: what are the characteristics of the best assays?
Which libraries should be screened and why? Small molecule and/or genetic screening?
What are key considerations and strategies for phenotypic screening hit triage and validation?
Which criteria should be met before investing in a compound series? How to best approach SAR without an identified target?
What are key considerations and strategies for target/mechanism identification and validation? Polypharmacology: friend or foe?
What are key considerations and strategies for phenotypic program progression (e.g. safety derisking, clinical trials)?